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promote  lifespan  extension  and  to  protect  from  metabolic  challenges.  Circulating  IGF‐1  and  SirT1  play  antagonizing
biological  roles  and  share  molecular  targets  in  the  heart,  in  turn  affecting  cardiomyocyte  physiology.  However,  how
different IGF‐1 isoforms may impact SirT1 and affect cardiomyocyte function is unknown. Here we show that locally acting
mIGF‐1  increases  SirT1  expression/activity,  whereas  circulating  IGF‐1  isoform  does  not  affect  it,  in  cultured  HL‐1  and
neonatal  cardiomyocytes.  mIGF‐1‐induced  SirT1  activity  exerts  protection  against  angiotensin  II  (Ang  II)‐triggered
hypertrophy and against paraquat (PQ) and Ang II‐induced oxidative stress. Conversely, circulating IGF‐1 triggered itself
oxidative stress and cardiomyocyte hypertrophy. Interestingly, potent cardio‐protective genes (adiponectin, UCP‐1 and MT‐
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In response to age-associated stresses or dysfunction 
such as pressure/volume overload, myocardial 
infarction and cardiomyopathies, the heart undergoes 
adaptation processes that lead to pathological 
hypertrophy [1]. One of the main causes of cardiac 
dysfunction and cardiomyocytes loss is an imbalance 
between the generation of reactive oxygen species 
(ROS) and the antioxidant defenses in favor of the 
former [2]. Growing evidence demonstrate that 
oxidative stress and hypertrophy are mechanistically 
linked to each other in the heart [3, 4].  Several 
therapeutic strategies are now employed to counteract 
the deleterious effects of cardiac hypertrophy and 
oxidative stress, making therefore the analysis of 
specific cell signaling imperative to generate novel 
drugs. In this scenario, the insulin like growth factor-1 
(IGF-1) and Sirtuin -1 are novel important mediators of 
cell survival, oxidative stress, regeneration, and life-
span regulation [5] in several tissues including the heart. 
 
IGF-1 is a peptide hormone acting as a growth and 
differentiation factor [6]. The pleiotropic functions of 
IGF-1 are reflected in the intricate structure of the gene 
encoding it. The IGF-1 gene spans more than 70 kb, 
contains two promoters and has six exons, giving rise to 
multiple splicing variants. These splice variants all 
consist of the same unvarying core flanked by varying 
termini. IGF-1 isoforms are classified according to the 
N-terminal signal peptide (class 1 and 2) and to the C-
terminal extension peptides, Ea and Eb [6]. It is 
established that IGF-1 is both a systemic growth factor 
produced primarily by liver and a local growth factor 
functioning in an autocrine/paracrine manner in tissues 
such as heart and skeletal muscle [6]. Post-
transcriptionally, IGF-1 isoforms are cleaved to give a 
mature 70 amino acid core hormone (identical for all 
isoforms) devoid of both the signal peptide and the 
extension peptide. This mature hormone is released into 
the bloodstream and has been implicated in the 
restriction of life span [7]. Correspondingly, high levels 
of circulating IGF1 are associated with increased 
mortality and cardiovascular diseases in the elderly [8]. 
When expressed as transgenes in the cardiomyocytes, 
distinct IGF-1 isoforms result in diverse phenotypes, 
ranging from protection from hypertrophy to its 
exacerbation towards pathological states [6, 9-11]. The 
role of IGF-1 in cardiac oxidative stress is also debated: 
cardiomyocyte-specific IGF-1 overexpression has been 
reported to protect from angiotensin II (Ang II)-
mediated oxidative stress [12] but, on the contrary, 
severe circulating IGF-1 deficiency, as in hepatocyte-
specific IGF-1 knock-out mice, antagonizes oxidative 
stress and cell death in cardiomyocytes triggered by the 
potent oxidant agent paraquat (PQ) [13].  
 
The mIGF-1 isoform comprises a Class 1 signal peptide 
and a C-terminal Ea extension peptide [6]. It is highly 
expressed in neonatal tissues and in the adult liver, but 
decreases during aging in extra-hepatic tissues, where 
its expression is activated transiently in response to 
local damage [14].  Previous studies from our 
laboratory showed that continuous expression of mIGF-
1 throughout postnatal life did not produce significant 
perturbations in normal heart physiology and, in 
contrast to previous studies with other IGF-1 
transgenes. [11] did not progress to a pathological 
phenotype [15]. In response to injury however, 
molecular analysis revealed that mIGF-1 curtails the 
inflammatory response, enhances antioxidative cell-
defense by upregulation of adiponectin, uncoupling 
protein 1 (UCP1) and methallothionein 2 (MT-2), and 
induces cardiac tissue restoration by increasing the 
number of proliferative cells at the border zone of the 
infarcted heart [15]. Given the benefits of cardiac 
restricted mIGF-1 expression, we sought to elucidate 
the molecular targets of this isoform.   
 
Sirtuin 1 (SirT1) belongs to the sirtuin family of 
nicotinamide adenine dinucleotide NAD-dependent 
protein deacetylases, whose activation is considered 
beneficial for metabolic, neurodegenerative and 
inflammatory diseases and to augment longevity [5]. 
Moderate SirT1 activation in murine heart has been 
shown to protect from oxidative stress and angiotensin 
II (Ang II)-induced cell death [16, 17]. Intriguingly, 
SirT1 expression is increased in the hypertrophic heart 
of rodents and monkeys [16, 18], although its functional 
relevance is unclear. IGF-1 and SirT1 share downstream 
targets in cardiomyocytes, and this in turn may affect 
cardiovascular function [19]. It has been reported that 
SirT1 is also activated by the polyphenol resveratrol and 
by caloric restriction [20], whereas its induction is 
counteracted by circulating IGF-1 [20]. Moreover, the 
levels of circulating IGF-1 are lowered upon caloric 
restriction [21]. Hence, SirT1 and IGF-1 apparently 
play opposite biological roles, although there is no 
information on the impact of separate IGF-1 isoforms, 
acting locally or systemically, on cardiac SirT1. In 
particular, in this study we sought to test if the liver-
produced and fully processed IGF-1 core protein 
isoform, circulating in the blood stream, and the locally 
acting mIGF-1 isoform [14], could display distinct 
effects in the protection from hypertrophic and 
oxidative stress. We tested this in mouse HL-1 and 
primary neonatal cardiomyocytes, using Ang II and PQ 




www.impactaging.com                   44                                          AGING,   January 2010, Vol.2   No.1We found that SirT1 and mIGF-1 co-regulate 
cardiomyocyte survival and protection from damage. 
mIGF-1 overexpression protects HL-1 cardiac cells and 
neonatal mouse cardiomyocytes from the deleterious 
effects induced by hypertrophic (Ang II) and oxidative 
(PQ) stressors in a SirT1-dependent fashion. The 
beneficial activity of SirT1 is mediated by the activation 
of protective molecules such as UCP1, adiponectin and 
MT2 and is dependent on mIGF-1 expression. 
Interestingly, the circulating IGF-1 isoform does not 
regulate SirT1 expression and activity and it is not 
beneficial during hypertrophy and oxidative stress 
conditions. The in vitro system herein described uncovers 
a novel signaling cross-talk that suggests potential 




mIGF-1 increases SirT1 expression and catalytic 
activity in mouse cardiomyocytes  
 
It has been reported that SirT1 and IGF-1 share common 
downstream targets in cardiomyocytes [19], but 
antagonize each other’s activity [20, 21] by mechanisms 
so far unexplored. To elucidate the molecular interplay 
between the two molecules in cardiac tissue, we 
examined if SirT1 expression is affected in the heart of 
mice overexpressing the locally acting mIGF-1 isoform 
[15]. Analysis of nuclear extracts prepared from whole 
heart lysates of mIGF-1 transgenic (Tg) and wild type 
(WT) mice revealed increased SirT1 protein levels in 
mIGF-1 Tg mouse hearts compared to wild type 
littermates (Figure 1A). To correlate the overexpression 
of SirT1 in Tg hearts with its deacetylase activity, we 
analysed the deacetylation levels of the SirT1 targets, p53 
[25] and histone H1 [26]. The  increase in SirT1 
expression mediated by mIGF-1 correlated functionally 
with histone H1  and p53 deacetylation at Lys26 and 
Lys382 respectively (Figure 1A). To confirm a direct 
effect of mIGF-1 on SirT1 expression, we overexpressed 
mouse mIGF-1 in HL-1 cardiomyocytes [22]. mIGF-1 
was detected in the cell medium already 24 hours after 
transient transfection (Figure 1B), and correlated with   
increased SirT1 expression (Figure 1C). Interestingly, 
treatment with 20 ng/ml of the circulating IGF-1, 
although induced comparable activation of the IGF-1 
receptor to that seen with transfected mIGF-1 (Figure 
1D), and moderately decreased SirT1 expression (Figure 
1C), indicating that mIGF-1 activates differential 
downstream signaling compared to the circulating 
peptide. Consistently with the results observed in whole 
heart lysates from mIGF-1 Tg mice, mIGF-1 
overexpression in HL-1 cells promoted decreased 
deacetylation of H1 and p53 at critical lysine residues 
(Figure 1C), whereas treatment with circulating IGF-1 
induced a moderate upregulation of acetylation levels of 
both SirT1 targets. Unmodified acetylation levels of p53 
and histone H1 were observed in cells overexpressing a 
catalytic inactive SirT1 protein (H363Y) [20] (Figure 
1C). These findings demonstrate that the locally acting 
mIGF-1 isoform, but not the circulating form, enhances 
SirT1 expression and activity in cardiomyocytes. 
 
mIGF-1/SirT1 pathway inhibits Ang II-induced 
hypertrophic fetal gene expression program 
 
Circulating IGF-1 and SirT1 have both been implicated 
in the protection against cardiac hypertrophy [10, 17], 
although the role of IGF-1 and/or its isoforms in this 
process remains controversial [6, 9-11]. A molecular 
hallmark of the progression to cardiac hypertrophy 
towards heart failure is the re-activation of the ‘fetal’ 
gene program in cardiomyocytes [27]. This process 
involves an upregulation of genes encoding atrial and 
brain natriuretic peptides (ANP and BNP), as well as 
fetal contractile protein isoforms such as α-myosin 
heavy chain 7 (MYH7) and α-skeletal actin (ACTA-1) 
is observed. In parallel, cardiac hypertrophy correlates 
with downregulation of adult α-myosin heavy chain 
(MYH6) and sarco/endoplasmic reticulum calcium 
ATPase-2 (SERCA2) [27]. Since Ang II is a potent 
hypertrophic agonist in cardiomyocyte, inducing re-
activation of the fetal gene program [28], we 
investigated the role of mIGF-1-induced SirT1 
expression on the Ang II-dependent fetal gene 
activation in two different in vitro models: in the HL1 
cell line, resembling adult cardiomyocytes, and in 
mouse WT and Tg neonatal cardiomyocytes. 
 
When HL-1 cardiomyocytes were exposed for 24 hours 
to Ang II at 1 μM, a supra-physiological but fairly used 
concentration to elicit its signaling and hypertrophic 
effects in cardiomyocytes studies [29, 30], the hormone 
triggered an increase in the mRNA levels of BNP 
(262±14%), ANP (265±6%), ACTA1 (189±10%) and 
MYH7 (164±9%) when compared to untreated cells 
(CTL), and a decrease in SERCA2 (30±9%) and MYH6 
(50±4%) transcript levels when compared to CTL cells 
(Figure 2A). Over-expression of locally acting mIGF-1 
or SirT1, but not the catalytic mutant SirT1 H363Y, 
fully prevented the activation of Ang II-induced fetal 
gene program (Figure 2A).  Importantly, overexpression 
of mIGF-1 and SirT1 H363Y together did not block the 
changes in gene expression induced by Ang II, 
indicating that mIGF-1 protective effect is SirT1-
dependent (Figure 2A). In contrast, exposure of HL-1 
cells to the circulating form of IGF-1, similarly to Ang 
II, triggered to some extent the activation of the fetal 















































In a second in vitro model, 2 day-old WT and Tg hearts 
were excised and cardiomyocytes extracted. Cultured 
cells were exposed for 24 hours to 1 μM Ang II and 
fetal gene activation analysed by quantitative real-time 
PCR (qRT-PCR). As expected Ang II treatment 
increased BNP (276±7%), ANP (306±27%), ACTA 
(178±15%) and MYH7 (161±16) transcript levels 
compared to untreated WT cells (Figure 2B). We 
observed in parallel a decrease in SERCA2 (53±6%) 
and MYH6 (61±4%) mRNA levels compared to WT 
untreated cardiomyocytes (Figure 2B). As in the HL-1 












































fully prevented the activation of the fetal gene program 
induced by Ang II (Figure 2B), indicating that mIGF-1 
activates antagonist signaling to hypertrophy during the 
early stages of cardiac development. These data 
correlates with previous analyses in our laboratory. 
Although mIGF-1 is known to induce a moderate 
physiological overgrowth in adult hearts [15], neonatal 
mIGF-1 expressing hearts do not present increased 
ANP, BNP and ACTA-1 transcript levels (data not 
shown). Interestingly, treatment of wild type cardio-
myocytes with the circulating IGF-1 induced activation 




acetyl‐H1(Lys26)/H1  and  acetyl‐p53(Lys382)/p53  levels  in  cardiomyocytes  from  mIGF‐1  mice,  expressed  as  %  of  those  in  wild  type
cardiomyocytes. (B) representative Western Blot of mIGF‐1 detected in the extracellular medium of HL‐1 cardiomyocytes, transfected with a
plasmid carrying mouse mIGF‐1 cDNA. (C) Left panel: representative Western Blot of SirT1, histone H1, acetyl‐H1 (Lys26) detected in nuclear
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Ang II-induced fetal gene program in neonatal cardio-
myocytes were dependent on SirT1, WT and mIGF-1 Tg 
cardiomyocytes were treated with two SirT1 pharmacolo-
gical inhibitors, pan-sirtuin inhibitor (sirtinol, 100 μM) or 
a SirT1 specific inhibitor (EX-527, 1 μM) [31], prior to 
exposure to Ang II.  At these concentrations, both 
compounds did not affect cardiomyocyte viability and 
blocked SirT1 activity, as assessed by increased acetyla-













































H1 (Lys26) (data not shown). Upon SirT1 blockade, Ang 
II treatment induced a significant increase in fetal-like 
genes in both wild type and mIGF-1 Tg car-diomyocytes, 
overcoming mIGF-1 protection (Figure 2B).  
 
Taken together, these data support the concept that the 
locally acting mIGF-1 isoform, but not the circulating 
liver-produced IGF-1, counteracts the activation of the 














































Figure  3.  mIGF‐1  prevents  Ang  II‐ and  IGF‐1‐
induced cell hypertrophy (MF‐20 staining) in HL‐
1  cardiomyocytes.  (A)  HL‐1  cardiomyocytes  were
transfected  or  treated  as  in  Legend  of  Figure  2A.
Sarcomeric  myosin  was  stained  with  MF‐20  antibody
and  images  were  acquired  using  a  Leica  confocal
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triggered by Ang II or IGF-1 
  
Cardiomyocyte hypertrophy is typically characterized by 
cell enlargement and increase in total sarcomeric myosin 
heavy chain. Here, we sought to determine the impact of 
mIGF-1-induced SirT1 expression on cell hypertrophy 
response by two complementary approaches, measure-
ment of MF-20 (a monoclonal antibody staining 
sarcomeric myosin heavy chain) immunoreactivity, and 
radioactive [3H]-leucine incorporation into cellular 
proteins. Exposure of HL-1 cardiomyocytes to Ang II led 
to an increase in cell size as assessed by MF-20 staining 










































total HL-1 cells died when treated with this hormone (see 
Figure 8), indicating that Ang II is both a pro-apoptotic 
and pro-hypertrophic agonist at 1 µM concentration. 
When mIGF-1 or SirT1 were overexpressed in HL-1 
cells, a full blockade of cell size increase induced by Ang 
II was observed (Figure 3A and B), whereas the catalytic 
inactive SirT1 H363Y was unable to prevent Ang II-
triggered cell hypertrophy (Figure 3A and 3B).   
Interestingly, the circulating IGF-1 isoform led to HL-1 
cell hypertrophy (Figure 3A and 3B). Similar results 
were obtained with [3H]-leucine incorporation 
experiments (Figure 4A), confirming that mIGF-1 
induced SirT1 activity prevents Ang II- and IGF-1-










































Figure  4.  mIGF‐1  prevents  Ang  II‐ and  IGF‐1‐
induced cell hypertrophy ([3H]‐leucine incorpora‐








mIGF‐1  Tg  mice  were  treated  with  SirT1  inhibitors
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cell hypertrophy was investigated as well in neonatal 
primary cardiomyocytes (Figure 5A-C and Figure 4B). 
mIGF-1 Tg cardiomyocytes were unresponsive to Ang II-
induced cell hypertrophy as indicated by MF-20 staining 
(Figure 5A and 5B), while blocking SirT1 activity with 
sirtinol or EX-527 restored Ang II-induced hypertrophy 
(Figure 5A and 5B), indicating that mIGF-1 inhibitory 















































on -SirT1 activity also in primary cardiomyocytes. In 
addition, exposure of wild type neonatal cardiomyocytes 
to the circulating form of IGF-1, triggered cell hypertro-
phy (Figure 5A and 5B). Similar findings were observed 
with [3H]-leucine incorporation experiments (Figure 4B). 
Therefore, using two different experimental approaches, 
we found that SirT1 activity induced by mIGF-1, but not 
by liver-produced IGF-1 isoform, displays anti-


































































































mIGF-1/SirT1 pathway prevents reactive oxygen 
species (ROS) generation, peroxidation products and 
cell death triggered by oxidative stressors 
  
ROS generation and oxidative stress contribute to the 
progression of pathological cardiac hypertrophy and 
heart failure. Indeed, oxidative stress and hypertrophy 
are intimately linked in cardiac muscle [3]. It is 
increasingly appreciated that the Ang II hypertrophic 
effects on cardiomyocytes are strictly dependent on the 













































tion, although it is controversial if this growth factor 
antagonizes or favors oxidative stress in cardiomyocytes 
[12, 13]. Since SirT1 overexpression has been reported 
to protect the murine heart from PQ-induced oxidative 
stress [16], we measured ROS content by dichlo-
rofluorescein diacetate (CM-DCFDA) method in mouse 
cardiomyocytes to shed light on the impact of IGF-
1/SirT1 signaling on oxidative stress generated by Ang 
II and by PQ. To this end, HL-1 or neonatal 
cardiomyocytes were pretreated with superoxide anion 
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Ang II and PQ triggered a significant augmentation in 
intracellular ROS compared to untreated control cells, 
which was fully blocked by Tiron (Figure 6A-B, and 
6C-D, for HL-1 and neonatal cardiomyocytes, 
respectively). mIGF-1 did not induce ROS production 
and efficiently prevented ROS generation by Ang II and 
PQ in both cardiomyocytes models (Figure 6A-D). 
Similarly, also SirT1 overexpression reversed ROS 
production in HL-1 cardiomyocytes (Figure 6A and B). 
In addition, blocking SirT1 enzymatic activity, by 
overexpression of SirT1 H363Y in HL-1 cells or 
incubation with SirT1 inhibitors in neonatal 
cardiomyocytes, abrogated the protective effects of 
mIGF-1 against Ang II- and PQ-induced intracellular 
ROS generation (Figure 6A-D). In contrast to locally 
acting mIGF-1 isoform, incubation of cardiomyocytes 
with the circulating IGF-1 isoform triggered a 





































than that generated by Ang II or by PQ (Figure 6A and 
C). Taken together, these data clearly indicate that 
mIGF-1, but not IGF-1, shields mouse cardiomyocytes 
from a rise of intracellular ROS generated by oxidative 
stressors.  To ascertain if mIGF-1 exerts a cardio-
protective role against oxidative stress as well in vivo, 
we injected peritoneally wild type and mIGF-1 Tg mice 
with PQ, and we assessed lipid and protein peroxidation 
levels, normally increasing upon ROS generation in 
cardiomyocytes [33]. Immunoblot analyses of lipid 
peroxidation 4-hydroxy-2-nonenal (4-HNE) and 
malondialdehyde (MDA) protein adducts in the heart 
showed that the levels of both protein adducts were 
significantly increased in the heart of PQ-injected wild 
type mice, whereas hearts of mIGF-1 Tg mice were to 
some extent protected from forming these compounds 
upon PQ injection (Figure 7). These data indicate that 
mIGF-1 protects the murine heart from oxidative stress 























































































ROS-mediated oxidative stress may lead to 
cardiomyocyte cell death [34]. Therefore, we examined 
if ROS production induced by Ang II, PQ and IGF-1 
contributed to mouse cardiomyocyte cell necrosis and 
examined the role of mIGF-1/SirT1 signaling in this 
process. HL-1 or neonatal mouse cardiomyocytes were 
preincubated with Tiron before adding Ang II or PQ for 
24 hours (Figure 8A-D). Consistently with ROS data, 
Ang II and PQ induced necrosis in 30% and 50% of the 
total cell population respectively, as assessed by flow 
cytometry with propidium iodide (PI) (Figure 8A-B, 
and 8C-D, for HL-1 and neonatal cardiomyocytes, 











































viability and efficiently prevented Ang II- and PQ-
induced necrosis (Figure 8A-D). Moreover, SirT1 
overexpression protected HL-1 cardiomyocytes from 
Ang II- and PQ-dependent cell necrosis (Figure 8A and 
B). When SirT1 activity was inhibited by sirtinol or by 
SirT1 H363Y in both HL-1 cells and neonatal cardio-
myocytes, no beneficial effect of mIGF-1 to Ang II- and 
PQ-induced cell death was observed (Figure 8 A-D). 
Interestingly, despite generating intracellular ROS, the 
circulating IGF-1 isoform did not impact cell viability 
(Figure 8A and C). In summary, mIGF-1/SirT1 
signaling protects cardiomyocytes from cell death 




















































Activation of cardio-protective genes by mIGF-
1/SirT1 
  
Next, we examined if the activation of cardio-protective 
mediators/effectors by mIGF-1 is dependent on SirT1 
signaling, mining our previous Affymetrix analysis of 
mRNA transcripts in the heart of mIGF-1 Tg mice 
versus wild type littermates [15]. Among the 
upregulated transcripts in the heart of mIGF-1 Tg mice, 
we focused on three cardio-protective genes whose 
expression was significantly (2- to 4- fold) increased: 













































ac expression of UCP1, MT2 and adiponectin mRNA 
levels was confirmed in mIGF-1 transgenic hearts 
compared to WT (Figure 9A). In cardiomyocytes from 
mIGF-1 Tg mice, inhibition of SirT1 activity lowered 
adiponectin, UCP-1 and MT-2 mRNAs to wild type 
levels, indicating that their upregulation by mIGF-1 is 
tightly dependent on SirT1 activity (Figure 9A). On the 
other hand, exposure of neonatal cardiomyocytes to 
circulating IGF-1 did not alter adiponectin, UCP-1 and 
MT-2 mRNA levels (Figure 9A). Consistently, 
overexpression of mIGF-1 in HL-1 cardiomyocytes led 
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9B). SirT1 overexpression in HL-1 cardiomyocytes also 
triggered an increase in these mRNAs (Figure 9B). 
Conversely, overexpression of SirT1 H363Y did not 
affect mRNA expression of these genes and blocked 
their upregulation by mIGF-1 (Figure 9B). 
 
To elucidate if mIGF-1 could upregulate mRNA levels 
through SirT1-dependent promoter activation, we 
transiently transfected neonatal cardiomyocytes and HL1 
cells with constructs carrying the minimal promoter 
region of the three genes, driving the firefly luciferase 
expression (see Table II). The analysis showed that 









































genes, as indicated by a substantial increase in luciferase 
activity (Figure 9C and Figure 10). Luciferase activation 
by mIGF-1 was tightly dependent on SirT1 function, 
since inhibition strategies (overexpression of SirT1 
H363Y in HL-1 cardiomyocytes and SirT1 inhibitors in 
neonatal cardiomyocytes) blocked the increase in 
adiponectin, UCP-1 and MT-2- promoter-driven 
luciferase activity (Figure 9C and Figure 10). In contrast 
to mIGF-1 isoform, the circulating form of IGF-1 did not 
alter the promoter activity of adiponectin, UCP-1 and 
MT-2 in mouse cardiomyocytes (Figure 9C and Figure 
10). We conclude that mIGF-1, but not IGF-1, activates 
at least some cardioprotective genes through SirT1-
















































































Hypertrophy and oxidative stress are intertwined 
processes in cardiomyocytes [3, 4], contributing to heart 
disease progression [1, 2]. In this study, we have 
identified a signaling pathway efficiently protecting 
mouse cardiomyocytes from oxidative and hypertrophic 
stresses (Ang II and PQ) that relies on the activation of 
NAD-dependent deacetylase SirT1 by the locally acting 
mGF-1 isoform. We show that mIGF-1-dependent 
SirT1 activation reduces ROS levels and cell death 
triggered by Ang II and PQ, and prevents Ang II-
induced hypertrophic response (Figure 11). Our report 
is consistent with others showing that SirT1 display 
cardio-protective effects against oxidative stress-
dependent cell death [16-18], and that SirT1 may elicit 
protection from cell hypertrophy by restoring MYH7 
expression [38]. Interestingly, in smooth muscle cells 
SirT1 inhibits the expression of Ang II type 1 receptor 
[39], but if a similar mechanism occurs in cardio-
myocytes remains to be established (Figure 11). We 
demonstrated that SirT1 counteracts both Ang II-




































cell death. The dual roles of Ang II as a pro-
hypertrophic and pro-apoptotic agent may rely on the 
cross-talk between the EGF receptor and the different 
PI3K isoforms (α, β, γ and δ) [40], leading in turn to 
hypertrophic growth or alternatively to cell death. 
Recently, it has been shown that other sirtuins family 
members (SirT3 and SirT7), play an important 
protective role against cardiac pathology [41, 42], 
indicating that mIGF-1-mediated protective effects 
against oxidative and hypertrophic stresses could be in 
part due to other members of this family. However, our 
data showed that a specific SirT1 inhibitor (EX-527) or 
overexpression of dominant negative SirT1 protein 
(H363Y) can reverse mIGF-1 protective effects, 
supporting a SirT1-specific mechanism. 
 
Importantly, our analysis showed that the locally 
produced mIGF-1 and the circulating IGF-1 have 
different roles in SirT1-mediated activity and cardiac 
protection. Although circulating IGF-1 and mIGF-1 
trigger phosphorylation of the same receptor(s) (Figure 
1C), differences in their respective signaling 
mechanisms leading to changes in SirT1 expression/acti- 
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respect, it is important to stress that while circulating 
IGF-1 activates typically PI3K/AKT/mTOR and MAPK 
pathways [43], locally acting mIGF-1 does not activate 
these canonical pathways in cardiomyocytes, impinging 
instead on PDK1 and SGK1 signaling [15]. Thus, 
divergent signaling mechanisms could explain the 
apparently antagonistic roles of the two IGF-1 isoforms 
in cardiomyocytes, with mIGF-1 able to prevent 
circulating IGF-1-induced cell hypertrophy. We have 
previously reported that mIGF-1 induced accelerated 
cardiac growth, related to higher expression levels of 
ANP at 1 and 2 months, without any further significant 
change [15]. Interestingly, in the in vitro models herein 
described mIGF-1 did not elicit increased hypertrophic 
markers and cell size in both neonatal and adult (HL1) 
cardiomyocytes, indicating that the in vivo response is 
mainly due to specific physiological signaling occurring 
during cardiac development.  Further work using in vivo 
and in vitro cardiac models is necessary to shed light on 
the intermediate players between mIGF-1-dependent 
signaling and SirT1 in cardiomyocytes (Figure 11). It 
would be important to understand whether some 
specific effects of mIGF-1 could be recapitulated by its 
N-terminal Class 1 signaling or C-terminal Ea extension 
peptides alone [6], which are absent in cleaved 
circulating IGF-1. It would be of interest also to 
ascertain if our data on mIGF-1/SirT1-dependent 
protection against oxidative and hypertrophic 
challenges can be confirmed in an in vivo setting, where 
circulating and autocrine/paracrine factors, absent in 
cultured cell systems, may have an impact.  
 
mIGF-1 Tg mice display activation in the heart of genes 
involved in anti-apoptotic and anti-oxidant defenses 
[15]: among the most upregulated, we focused on 
adiponectin, UCP-1 and MT-2 [15]. Although these 
proteins are functionally unrelated (adiponectin is a 
hormone regulating metabolic processes, UCP-1 is a 
mitochondrial protein allowing protons to reenter the 
mitochondrial matrix short-circuiting the respiratory 
chain, and MT-2 is a zinc-binding protein), remarkably 
they have been reported independently to exert 
protection against hypertrophic and oxidative stresses in 
the heart [35-37]. Strikingly, we found that the 
activation of these genes by mIGF-1 relies on SirT1-
dependent activation of their promoters, suggesting that 
at least some of the mIGF-1 dependent transcriptional 
program in cardiomyocytes is mediated by SirT1. Our 
data are in agreement with the finding that SirT1 
upregulates adiponectin [44], whereas to our knowledge 
this is the first report about the SirT1-dependent 
regulation of UCP-1 and MT-2 transcripts.  
 
In conclusion, there is increasing evidence that NAD-
regulated enzymes such as SirT1 finely interplay in the 
regulation of cardiomyocyte function [17, 45], and their 
role begins now to be appreciated. Consequently, 
research on the role of IGF-1 isoforms in this “NAD 
world” is also in its infancy. This domain is considered 
of clinical interest for the treatment of cardiovascular 
diseases [5, 46], and the mIGF-1/SirT1 pathway 
presented in this study may represent a promising 
therapeutic target to fight cardiac hypertrophy and 
oxidative stress. 
 
MATERIALS AND METHODS 
 
Animals. Transgenic FVB mice carrying a rat mIGF-1 
cDNA driven by the mouse α-MyHC promoter were 
generated and maintained as previously described [11].  
 
Western analyses. Protein extraction from whole cell or 
heart tissue preparation was performed in RIPA buffer 
(1% (w/w) Nonidet P40, 1% (w/w) Sodiumdeoxycate, 
0.1% (w/v) SDS, 150mM NaCl, 50mM HEPES pH 7.0, 
2mM EDTA pH 8.0, 100mM NaF, 10% glycerol, 
1.5mM MgCl2, 100mM PMSF in ETOH, 200mM 
sodium orthovanadate, 1 µg/ml aprotinin). For analyses 
of nuclear proteins (SirT1, H1), nuclear fraction was 
isolated from cultured cells or heart tissues according to 
the following procedure:  cells or liquid nitrogen-
powderized heart tissues were dissolved in buffer A (10 
m M  H E P E S ,  1 . 5  m M  M g C l 2 ,  1 0  m M  K C l ,  0 . 5  m M  
DTT, 0.05% NP-40, 100mM PMSF in ETOH, 200mM 
sodium orthovanadate, 1 μg/ml aprotinin, pH 7.9) and 
left on ice for 10 min. After centrifugation, cytoplasmic 
fraction (supernatant) was kept aside and frozen. Pellets 
were resuspended in buffer B (5 mM HEPES, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 26% glycerol 
(v/v), 100mM PMSF in ETOH, 200mM sodium 
orthovanadate, 1 mg/ml aprotinin, pH 7.9) plus NaCl to 
give a final concentration of 300mM NaCl. Lysates 
were then mechanically homogenized with a Dounce 
homogenizer on ice; samples were left on ice for 30 
min. After a final centrifugation, supernatant (nuclear 
fraction) was collected for further analysis. Protein 
concentration was determined using Bradford method 
(Biorad) and 20 mg of protein lysates were separated in 
SDS polyacrylamide mini-gel (Biorad system) and 
transferred onto a hybond ECL nitrocellulose membrane 
(Amersham). Membranes were blocked with 5% milk, 
blotted with specific antibodies o/n at 4oC, washed 3 
times with washing buffer (TBS and 0,1% Tween-20) 
for 30 min and blotted with specific secondary 
antibodies (horseradish peroxidase-conjugated, 1:5000) 
with 5% milk for 1h at RT. The membrane was 
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HL-1 was cultured as previously described, on 
gelatin/fibronectin coated flasks or multi-wells plates 
[22]. For transient plasmid transfection or co-transfec-
tion experiments, the lipid-based reagent Lipo-
fectamineTM 2000 (Invitrogen) was used, according to 
manufacturer instructions. For luciferase assays, 2 x 106 
cells/well were transfected with 1 µg of luciferase 
reporter constructs and 1µg of pRL-TK (Renilla 
luciferase construct from Promega). Luciferase assays 
were performed 48 hours after transfection using a dual-
luciferase reporter assay (Promega) and a luminescence 
counter VictorTM Light 1420 (Perkin Elmer). Firefly 
luciferase activity was normalized to renilla luciferase 
expression for each sample. 
 
Preparation of primary neonatal cardiomyocytes 
culture. One-day-old C57/Bl6 or mIGF-1 transgenic 
mice were sacrificed and hearts were excised. After 
scalpel homogenization, ventricular cardiomyocytes 
were isolated following a series of collagenase/pancre- 
atin digestions (Collagenase type II, CSL2, 
Worthington/Pancreatin 4x NF, GIBCO) and cells 
were collected by centrifugation (8.000rpm for 5min). 
Next, fibroblasts were removed from the culture after a 
45 min pre-plating step at 37°C in complete medium 
[DMEM/199 medium (5/1 ratio) supplemented with 
10% heat inactivated horse serum (Sigma), 5% heat 
inactivated fetal calf serum (Sigma), 0.025 M HEPES, 
0.002M L-glutamine (Sigma) and 1x penicil-
lin/streptomycin (Sigma)]. Alive cardio-myocytes 
were counted using Tryptan Blue solution (Sigma). 
Cells were transferred on 1% gelatin (Sigma) -coated 
12- or 96-well plates. 
 
Reactive oxygen species (ROS) measurements. The 
fluorescent probe dichlorofluorescein diacetate (CM-
DCFDA, Sigma) was used to monitor the intracellular 
generation of reactive oxygen species (ROS). HL-1 or 
neonatal mouse cardiomyocytes, grown on coated 96-
wells plates were transfected and/or treated for 60 
minutes with Angiotensin II (1 mM, 60 min) or 
paraquat (100 mM) as described, with or without 10 
mM superoxide scavenger Tiron. After washing with 
PBS, cells were incubated 20 min in the dark with 10 
mM CM-DCFDA. Cells were washed again with PBS 
and fluorescence was detected at excitation/emission 
wavelength of 485-535nm in a fluorimeter Fluoroskan 
Ascent PL (Labsystems). Fluorescence values were 
normalized to protein content for each well. 
 
[3H]-leucine incorporation. The cells (HL-1 or neonatal 
mouse cardiomyocytes) were plated on 12-well-coated 
dishes at a density of 100 cells/mm2. Protein synthesis 
was measured by [3H] Leucine (1 μCi/ml) incorpora-
tion as described elsewhere [23].  
 
MF-20 immunostaining and confocal microscopy. 
Cells (HL-1 or neonatal mouse cardiomyocytes) were 
plated on coated coverslips. Upon the indicated 
treatment/transfection, cells were washed twice in PBS 
and fixed with 4% paraphormaldheyde for 10 min ice. 
Blocking was performed in PBS calcium free plus 
10% goat serum, followed by 1 h incubation at RT 
with the MF-20 antibody diluted 1/250 in PBS calcium 
free plus 1.5% goat serum, and by 45 min incubation 
at RT with secondary Cy3 antibody (red) diluted 1/300 
in PBS plus 1%BSA and 0.2% Triton-X. Coverslips 
were mounted on microscopy slides and confocal 
images were acquired on a Leica TCS SP5 
microscope. Cell size (total area) and cell hypertrophy 
(total MF-20 staining intensity) were accurately 
quantified using the Metamorph® imaging software 
(Molecular Devices).  
 
Cell viability assay. Cell viability/cell death was 
quantified by staining HL-1 cells or neonatal mouse 
cardiomyocytes with propidium iodide (Invitrogen) 
following cell transfections and/or treatments as 
indicated. Fluorescent intensity was analyzed using the 
BD FACSCanTM System. All FACS data was analyzed 
with FlowJo (Tree Star, USA). 
 
Real-Time PCR. Total RNA was isolated from hearts 
using TRIzol (Invitrogen). Afterwards, the RNA was 
treated with DNaseI enzyme (Promega) for 1h at 37oC 
and then cleaned by column purification (Qiagen). The 
RNA concentration was determined with a 
spectrophotometer. After RNA quality verification, 1-2 
mg was used to prepare cDNA (Ready-To-Go, T-
Primed First-Strand Kit, Amersham Bioscience). 
Quantitative polymerase chain reaction (PCR) was 
performed using the SYBR Green (SIGMA) in a Light-
Cycler (Roche). UbiC, Rn18S and GAPDH transcripts 
were used as internal controls, according to the GeNorm 
method [24]. Primer sequences were designed with the 
Primer 3 software (http://frodo.wi.mit.edu/) and are 
listed in Table I. 
 
Statistical analysis. Results are expressed as means ± 
S.E. Comparisons were made by using appropriated 
Student’s t test. Differences were considered as 
significant when P<0.05 (*), P<0.01 (**) or P<0.001 
(***).  
 
Reagents, antibodies and plasmids. All reagents, 
antibodies and plasmids not described elsewhere in the 














































































Mouse Forward  Reverse 





























5’ CTCCACGAACAGCTTCACAA 3’ 
UCP-1  5’ GGGCCCTTGTAAACAACAAA 3’  5’ GTCGGTCCTTCCTTGGTGTA 3’ 
MYH6  5’ GAGGACCAGGCCAATGAGTA 3’  5’ GCTGGGTGTAGGAGAGCTTG 3’ 
MYH7  5’ TGCAGCAGTTCTTCAACCAC 3’  5’ TCGAGGCTTCTGGAAGTTGT 3’ 
Adiponectin  5’ GTTGCAAGCTCTCCTGTTCC 3’  5’ TCTCCAGGAGTGCCATCTCT 3’ 
Metallothionein-2  5’ CCATATCCCTTGAGCCAGAA 3’  5’ ATCGACGAGAGATCGGTTTG 3’ 
Acta-1  5’ GCATGCAGAAGGAGATCACA 3’  5’ TTGTCGATTGTCGTCCTGAG 3’ 
ANP  5’ CCTAAGCCCTTGTGGTGTGT 3’  5’ CAGAGTGGGAGAGGCAAGAC 3’ 
BNP  5’ CAGCTCTTGAAGGACCAAGG 3’  5’ AGACCCAGGCAGAGTCAGAA 3’ 
SERCA2a  5’ CTGTGGAGACCCTTGGTTGT 3’  5’ CAGAGCACAGATGGTGGCTA 3’ 
UbiC   5’ AGCCCAGTGTTACCACCAAG 3’  5’ GCAAGAACTTTATTCAAAGTGCAA 3’ 
GAPDH  5’ AACTTTGGCATTGTGGAAGG 3’  5’ ACACATTGGGGGTAGGAACA 3’ 





Protein targeted  Host  Clone Provider  Catalogue 
number 
SirT1 mouse  B-7  Santa  Cruz  Biotechnology  sc-74465 
H1 goat  N-16  Santa  Cruz  Biotechnology  sc-34464 
acetyl-H1 (Lys26)  rabbit  -  Sigma  H-7789 
Adiponectin rabbit  -  Sigma  A6354 
UCP-1 rabbit    Sigma  U6382 
p53 rabbit  -  Cell  Signaling  #9282 
acetyl-p53 (Lys382)  rabbit  -  Cell Signaling  #2525 
MF-20 mouse  -  DSHB  from:  Fischman, 
D.A. 
IGF-1 goat  -  Sigma  12157 
IGF-1 receptor  rabbit  -  Cell Signaling  #3027 
phospho-IGF-1 receptor 
(Tyr1135/1136) 
rabbit -  Cell  Signaling  #3024 
 
Secondary antibodies:  
 
Protein targeted  Host  Provider  Catalogue number 
HRP-conjugated anti-mouse   Goat  Amersham – GE Healthcare  NA9310V 
HRP-conjugated anti-rabbit   Goat  Amersham – GE Healthcare  NA934V 
HRP conjugated anti-Goat  Rabbit  Santa Cruz Biotechnology  sc-2020 
Cy3-conjugated Goat  Jackson ImmunoResearch  115-165-044 
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